ライフサイエンスコーパス: idiopathic pulmonary fibrosis

1 e response play roles in the pathogenesis of idiopathic pulmonary fibrosis.

2 em cells (LR-MSC) plays an important role in idiopathic pulmonary fibrosis.

3 were not correlated with disease severity of idiopathic pulmonary fibrosis.

4 RNA-related collagen V overexpression during idiopathic pulmonary fibrosis.

5 there is consideration of their use to treat idiopathic pulmonary fibrosis.

6 eir relationship with disease progression in idiopathic pulmonary fibrosis.

7 as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

8 proves the feasibility of clinical trials in idiopathic pulmonary fibrosis.

9 interstitial lung diseases, particularly for idiopathic pulmonary fibrosis.

10 n clinical trials and to guide management of idiopathic pulmonary fibrosis.

11 tween healthy controls and participants with idiopathic pulmonary fibrosis.

12 ease, and interstitial lung diseases such as idiopathic pulmonary fibrosis.

13 ration of two new drugs for the treatment of idiopathic pulmonary fibrosis.

14 s, thus avoiding surgery in the diagnosis of idiopathic pulmonary fibrosis.

15 ng inflammation characteristic of asthma and idiopathic pulmonary fibrosis.

16 or of or against treatment interventions for idiopathic pulmonary fibrosis.

17 of scar tissue in the lungs of patients with idiopathic pulmonary fibrosis.

18 gnatures were associated with progression of idiopathic pulmonary fibrosis.

19 l, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis.

20 fibroblasts from the lungs of patients with idiopathic pulmonary fibrosis.

21 stress is observed in lungs of patients with idiopathic pulmonary fibrosis.

22 engths are associated with worse survival in idiopathic pulmonary fibrosis.

23 as a diagnostic and prognostic biomarker of idiopathic pulmonary fibrosis.

24 progression-free survival, in patients with idiopathic pulmonary fibrosis.

25 treatment of human lung diseases, including idiopathic pulmonary fibrosis.

26 ine and acute exacerbations in patients with idiopathic pulmonary fibrosis.

27 es in interstitial lung disorders other than idiopathic pulmonary fibrosis.

28 tient receiving immunosuppression because of idiopathic pulmonary fibrosis.

29 ly as compared with placebo in patients with idiopathic pulmonary fibrosis.

30 epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.

31 rbates chronic pulmonary diseases, including idiopathic pulmonary fibrosis.

32 affect risk stratification of patients with idiopathic pulmonary fibrosis.

33 nd diseased lungs of patients suffering from idiopathic pulmonary fibrosis.

34 tivators of telomerase in therapies to treat idiopathic pulmonary fibrosis.

35 e gene encoding mucin 5B, is associated with idiopathic pulmonary fibrosis.

36 6 integrin is central to the pathogenesis of idiopathic pulmonary fibrosis.

37 everal cancers and other diseases, including idiopathic pulmonary fibrosis.

38 cause of the fibrotic changes that underlie idiopathic pulmonary fibrosis.

39 reatment options available for patients with idiopathic pulmonary fibrosis.

40 ated in fibroblasts from human subjects with idiopathic pulmonary fibrosis.

41 was also induced in myofibroblasts in human idiopathic pulmonary fibrosis.

42 dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis.

43 idiopathic cases of organ fibrosis, such as idiopathic pulmonary fibrosis.

44 telomere lengths of the Dallas patients with idiopathic pulmonary fibrosis (1.33 [SD 0.25]) were simi

45 erlying lung diseases included COPD (44.8%), idiopathic pulmonary fibrosis (22.9%), interstitial lung

46 on of mesenchymal cells are the hallmarks of idiopathic pulmonary fibrosis, a devastating disease of

47 In idiopathic pulmonary fibrosis, a fatal form of progressi

48 ncological indications and diseases, such as idiopathic pulmonary fibrosis, a number may hold promise

49 Idiopathic pulmonary fibrosis, a progressive and inevita

50 Patients with idiopathic pulmonary fibrosis aged 65 years and older we

51 transplant (aHR, 1.3; 95% CI, 1.0-1.7), and idiopathic pulmonary fibrosis (aHR, 1.4; 95% CI, 1.0-1.8

52 been suggested as a beneficial treatment for idiopathic pulmonary fibrosis, although data from placeb

53 ently used to inhibit TGF-beta signalling in idiopathic pulmonary fibrosis, ameliorated BK dysfunctio

54 incidence, prevalence, and mortality risk of idiopathic pulmonary fibrosis among US Medicare benefici

55 f two effective treatments for patients with idiopathic pulmonary fibrosis, an accurate diagnosis is

56 or adults aged 40-80 years with well-defined idiopathic pulmonary fibrosis and 5% or less honeycombin

57 l dysfunction and apoptosis are important in idiopathic pulmonary fibrosis and asbestosis.

58 elevated in lung biopsies from patients with idiopathic pulmonary fibrosis and bleomycin (BLM)-induce

59 during TGF-beta1-induced differentiation of idiopathic pulmonary fibrosis and CCD-19Lu fibroblasts.

60 ribute to EMT, ATII cells from patients with idiopathic pulmonary fibrosis and chronic obstructive pu

61 ought to contribute towards diseases such as idiopathic pulmonary fibrosis and chronic obstructive pu

62 and potential risk factors for diagnosis of idiopathic pulmonary fibrosis and death between 2001 and

63 ed vasculitis, systemic lupus erythematosus, idiopathic pulmonary fibrosis and dengue haemorrhagic fe

64 itoring disease progression in patients with idiopathic pulmonary fibrosis and emphysema extent great

65 RATIONALE: Patients with idiopathic pulmonary fibrosis and emphysema may have art

66 tation in lung disease that is recognized as idiopathic pulmonary fibrosis and emphysema.

67 mary fibroblasts obtained from patients with idiopathic pulmonary fibrosis and human lung CCD-19Lu fi

68 erstitial pneumonia pattern is a hallmark of idiopathic pulmonary fibrosis and is essential for its d

69 ibrotic areas of lungs of both patients with idiopathic pulmonary fibrosis and mice that are subjecte

70 The clinical course of idiopathic pulmonary fibrosis and nonspecific interstiti

71 ge-scale real applications in breast cancer, idiopathic pulmonary fibrosis and pan-cancer methylation

72 h 31, 2012, 189 had a confirmed diagnosis of idiopathic pulmonary fibrosis and were included in subse

73 onsible for collagen V overexpression during idiopathic pulmonary fibrosis, and these miRNAs may serv

74 also increased in the lungs of patients with idiopathic pulmonary fibrosis as compared to in normal h

75 atrix (ECM) turnover predicts progression of idiopathic pulmonary fibrosis as determined by change in

76 e up-regulated in the lungs of patients with idiopathic pulmonary fibrosis as well as in wound healin

77 ession, in telomere-related diseases such as idiopathic pulmonary fibrosis, as well as in mice and ot

78 irfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND 016; 52 weeks)-for

79 he etiology of degenerative diseases such as idiopathic pulmonary fibrosis, bone marrow failure, and

80 ngths are found in a subset of patients with idiopathic pulmonary fibrosis, but their clinical signif

81 everal chronic pulmonary diseases, including idiopathic pulmonary fibrosis, chronic obstructive pulmo

82 ndings were validated in the two independent idiopathic pulmonary fibrosis cohorts (Chicago and San F

83 in serum and lung tissue from patients with idiopathic pulmonary fibrosis compared to healthy volunt

84 ted levels in lung tissue from patients with idiopathic pulmonary fibrosis compared with control lung

85 in leukocytes in the lungs of patients with idiopathic pulmonary fibrosis compared with control lung

86 e increased in the serum of individuals with idiopathic pulmonary fibrosis compared with healthy cont

87 ns were related to subsequent progression of idiopathic pulmonary fibrosis (defined as death or decli

88 ative to control participants, patients with idiopathic pulmonary fibrosis demonstrate excessive mono

89 -onset ILD in India, followed by CTD-ILD and idiopathic pulmonary fibrosis; diagnoses varied between

90 dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis disrupt the binding betwee

91 d the apoptotic susceptibility of normal and idiopathic pulmonary fibrosis fibroblasts; blocked TGF-b

92 Drug Administration (FDA)-approved drug for idiopathic pulmonary fibrosis, for its therapeutic effec

93 on CT in a cohort of patients with suspected idiopathic pulmonary fibrosis from a previous randomised

94 d a pooled cohort study of 517 patients with idiopathic pulmonary fibrosis from three IPFnet multicen

95 n, 102 women; mean age, 69 years +/- 9) with idiopathic pulmonary fibrosis from two institutions.

96 placebo-controlled trials of IFN-gamma-1b in idiopathic pulmonary fibrosis (GIPF-001 [NCT00047645] an

97 The 149 patients with idiopathic pulmonary fibrosis had shorter telomere lengt

98 ently published placebo-controlled trials in idiopathic pulmonary fibrosis have established that pirf

99 nsplant-free survival time for patients with idiopathic pulmonary fibrosis (HR 0.22 [95% CI 0.08-0.63

100 terstitial lung disease diagnoses other than idiopathic pulmonary fibrosis (HR 0.73 [0.16-3.41]; p=0.

101 ght not be necessary to reach a diagnosis of idiopathic pulmonary fibrosis if high-resolution CT scan

102 e, 48.1% air coolers), CTD-ILD in 13.9%, and idiopathic pulmonary fibrosis in 13.7%.

103 Patients with idiopathic pulmonary fibrosis in a clinical trial of pre

104 The incidence and prevalence of idiopathic pulmonary fibrosis in people aged 65 years an

105 The annual incidence of idiopathic pulmonary fibrosis in the Medicare population

106 likely to be useful in routine management of idiopathic pulmonary fibrosis in the medium-term future

107 Published data for the epidemiology of idiopathic pulmonary fibrosis in the USA are scarce.

108 We analyzed the first 200 hits for "idiopathic pulmonary fibrosis" in Google, Yahoo, and Bin

109 pplying the concept of precision medicine to idiopathic pulmonary fibrosis, in particular to search f

110 ty (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this

111 onchoalveolar lavage fluid of a patient with idiopathic pulmonary fibrosis, indicating that these rea

112 h fibrosing ILD, including 456 patients with idiopathic pulmonary fibrosis (IPF) (men, 366; women, 90

113 The clinical features of idiopathic pulmonary fibrosis (IPF) and chronic hypersen

114 Despite shared environmental exposures, idiopathic pulmonary fibrosis (IPF) and chronic obstruct

115 ) cause telomere diseases including familial idiopathic pulmonary fibrosis (IPF) and dyskeratosis con

116 target genes are increased in patients with idiopathic pulmonary fibrosis (IPF) and in animal models

117 Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to

118 parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are

119 ious cause, such as the devastating diseases idiopathic pulmonary fibrosis (IPF) and scleroderma.

120 or the computed tomographic (CT) features of idiopathic pulmonary fibrosis (IPF) and to gain insight

121 ry-related hospitalizations of patients with idiopathic pulmonary fibrosis (IPF) are more frequent th

122 lung injury is related to poor outcome, and idiopathic pulmonary fibrosis (IPF) can be regarded as a

123 The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be appr

124 ted that lung fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) exhibit a hypermotil

125 rom the lungs of the patients suffering from idiopathic pulmonary fibrosis (IPF) exhibit enhanced FXI

126 PMCs from patients with idiopathic pulmonary fibrosis (IPF) exhibited increased

127 urgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice

128 lcysteine) is used with pirfenidone to treat idiopathic pulmonary fibrosis (IPF) in Europe.

129 RATIONALE: Idiopathic pulmonary fibrosis (IPF) involves the accumul

130 Idiopathic pulmonary fibrosis (IPF) is a chronic age-rel

131 Idiopathic pulmonary fibrosis (IPF) is a chronic and fat

132 Idiopathic pulmonary fibrosis (IPF) is a chronic and pro

133 RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic fatal l

134 Idiopathic pulmonary fibrosis (IPF) is a chronic lung di

135 Idiopathic pulmonary fibrosis (IPF) is a chronic progres

136 Idiopathic pulmonary fibrosis (IPF) is a chronic, progre

137 Idiopathic pulmonary fibrosis (IPF) is a chronic, progre

138 Idiopathic pulmonary fibrosis (IPF) is a common, progres

139 Idiopathic pulmonary fibrosis (IPF) is a deadly chronic

140 Idiopathic pulmonary fibrosis (IPF) is a deadly lung dis

141 Idiopathic pulmonary fibrosis (IPF) is a devastating dis

142 Idiopathic pulmonary fibrosis (IPF) is a devastating dis

143 Idiopathic pulmonary fibrosis (IPF) is a devastating dis

144 Idiopathic pulmonary fibrosis (IPF) is a devastating dis

145 Idiopathic pulmonary fibrosis (IPF) is a devastating lun

146 Idiopathic pulmonary fibrosis (IPF) is a devastating lun

147 Idiopathic pulmonary fibrosis (IPF) is a disease charact

148 Idiopathic pulmonary fibrosis (IPF) is a disease of prog

149 Idiopathic pulmonary fibrosis (IPF) is a fatal disease c

150 Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic

151 Idiopathic pulmonary fibrosis (IPF) is a fatal lung dise

152 Idiopathic pulmonary fibrosis (IPF) is a fatal progressi

153 Idiopathic pulmonary fibrosis (IPF) is a fibrosing inter

154 Idiopathic pulmonary fibrosis (IPF) is a form of progres

155 Idiopathic pulmonary fibrosis (IPF) is a lethal lung dis

156 Idiopathic pulmonary fibrosis (IPF) is a lethal, chronic

157 Idiopathic pulmonary fibrosis (IPF) is a lethal, fibropr

158 Idiopathic pulmonary fibrosis (IPF) is a progressive and

159 Idiopathic pulmonary fibrosis (IPF) is a progressive and

160 Idiopathic pulmonary fibrosis (IPF) is a progressive cli

161 Idiopathic pulmonary fibrosis (IPF) is a progressive dis

162 Idiopathic pulmonary fibrosis (IPF) is a progressive dis

163 Idiopathic pulmonary fibrosis (IPF) is a progressive fib

164 Idiopathic pulmonary fibrosis (IPF) is a progressive fib

165 Idiopathic pulmonary fibrosis (IPF) is a progressive int

166 Idiopathic pulmonary fibrosis (IPF) is a progressive lun

167 Idiopathic pulmonary fibrosis (IPF) is a progressive lun

168 Idiopathic pulmonary fibrosis (IPF) is a progressive par

169 Idiopathic pulmonary fibrosis (IPF) is a progressive, de

170 Idiopathic pulmonary fibrosis (IPF) is a progressive, fa

171 Idiopathic pulmonary fibrosis (IPF) is a progressive, fa

172 Idiopathic pulmonary fibrosis (IPF) is a progressive, fa

173 Idiopathic pulmonary fibrosis (IPF) is an age-related di

174 RATIONALE: Idiopathic pulmonary fibrosis (IPF) is an increasingly r

175 Idiopathic pulmonary fibrosis (IPF) is an untreatable an

176 Idiopathic pulmonary fibrosis (IPF) is characterized by

177 Development of idiopathic pulmonary fibrosis (IPF) is characterized by

178 Idiopathic pulmonary fibrosis (IPF) is characterized by

179 A hallmark of idiopathic pulmonary fibrosis (IPF) is excessive and dis

180 Idiopathic pulmonary fibrosis (IPF) is progressive and r

181 The clinical course of idiopathic pulmonary fibrosis (IPF) is unpredictable.

182 yofibroblastic differentiation of normal and idiopathic pulmonary fibrosis (IPF) lung fibroblasts.

183 rs, individuals might be diagnosed as having idiopathic pulmonary fibrosis (IPF) or chronic (fibrotic

184 In this exploratory analysis, adults with idiopathic pulmonary fibrosis (IPF) or chronic obstructi

185 pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF) or chronic obstructi

186 ted B cells have recently been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis.

187 lation has been demonstrated in the lungs of idiopathic pulmonary fibrosis (IPF) patients.

188 es in the lung microbial community influence idiopathic pulmonary fibrosis (IPF) progression.

189 be considered as the most exciting period in idiopathic pulmonary fibrosis (IPF) research.

190 geal reflux (GER) is higher in patients with idiopathic pulmonary fibrosis (IPF) than in matched cont

191 significance of a first-choice diagnosis of idiopathic pulmonary fibrosis (IPF) versus not IPF for M

192 Idiopathic pulmonary fibrosis (IPF), a chronic and progr

193 B cells are involved in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a progressive, rest

194 gs of human donors and patients with COPD or idiopathic pulmonary fibrosis (IPF), as well as in cigar

195 ides an updated approach to the diagnosis of idiopathic pulmonary fibrosis (IPF), based on a systemat

196 Mortality prediction is well studied in idiopathic pulmonary fibrosis (IPF), but little is known

197 BAL of patients with stable and progressive idiopathic pulmonary fibrosis (IPF), defined as <5% and

198 Fibrotic lung injury, such as in Idiopathic Pulmonary Fibrosis (IPF), is mediated through

199 are effective in slowing the progression of idiopathic pulmonary fibrosis (IPF), it remains a debili

200 Although aging is a known risk factor for idiopathic pulmonary fibrosis (IPF), the pathogenic mech

201 of lung fibrosis and in human subjects with idiopathic pulmonary fibrosis (IPF), we observed activat

202 expressed in lung tissues from patients with idiopathic pulmonary fibrosis (IPF), whereas PIAS4 prote

203 Current prediction models of mortality in idiopathic pulmonary fibrosis (IPF), which are based on

204 trol (fibrosis-free) donors or patients with idiopathic pulmonary fibrosis (IPF), which is a very agg

205 in PBMCs and lung tissues from patients with idiopathic pulmonary fibrosis (IPF), which was confirmed

206 be the critical link to the pathogenesis of idiopathic pulmonary fibrosis (IPF).

207 r a confident multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF).

208 actor for the development and progression of idiopathic pulmonary fibrosis (IPF).

209 thereby contributing to the pathogenesis of idiopathic pulmonary fibrosis (IPF).

210 patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF).

211 , has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

212 x, in particular collagens, is a hallmark of idiopathic pulmonary fibrosis (IPF).

213 plays a critical role in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

214 e in helping to identify patients with early idiopathic pulmonary fibrosis (IPF).

215 ne complex-mediated complement activation in idiopathic pulmonary fibrosis (IPF).

216 in E2 contributes to the fibrotic process in idiopathic pulmonary fibrosis (IPF).

217 mononuclear cells (PBMC) from patients with idiopathic pulmonary fibrosis (IPF).

218 Lymphocytes are increasingly associated with idiopathic pulmonary fibrosis (IPF).

219 ) received a transplant for the diagnosis of idiopathic pulmonary fibrosis (IPF).

220 antibodies are present in most patients with idiopathic pulmonary fibrosis (IPF).

221 isposition contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF).

222 monary fibrosis, so he is considered to have idiopathic pulmonary fibrosis (IPF).

223 tribute to the initiation and progression of idiopathic pulmonary fibrosis (IPF).

224 each been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

225 ing and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

226 e are associated with disease progression in idiopathic pulmonary fibrosis (IPF).

227 agen deposition in fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

228 plays a crucial role in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

229 s of human subjects with rapidly progressive idiopathic pulmonary fibrosis (IPF).

230 and trafficking has a newly defined role in idiopathic pulmonary fibrosis (IPF); however, the contri

231 y has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF); however, the repert

232 Idiopathic pulmonary fibrosis is a chronic, progressive

233 Idiopathic pulmonary fibrosis is a devastating disease,

234 Idiopathic pulmonary fibrosis is a devastating lung dise

235 Idiopathic pulmonary fibrosis is a devastating lung dise

236 Idiopathic pulmonary fibrosis is a disease characterized

237 Idiopathic pulmonary fibrosis is a fatal lung disease wi

238 Idiopathic pulmonary fibrosis is a progressive and gener

239 Idiopathic pulmonary fibrosis is a progressive fibrotic

240 Idiopathic pulmonary fibrosis is a prototype of chronic,

241 hese preliminary data suggest progression of idiopathic pulmonary fibrosis is associated with the pre

242 Idiopathic pulmonary fibrosis is characterized by a prog

243 A central pathway in the pathogenesis of idiopathic pulmonary fibrosis is epithelial injury leadi

244 f the lung microbiome in the pathogenesis of idiopathic pulmonary fibrosis is unknown.

245 The relevance of precision medicine to idiopathic pulmonary fibrosis is yet to be established,

246 we believe that the future of management for idiopathic pulmonary fibrosis lies in the development of

247 Idiopathic pulmonary fibrosis lung alveolar type II cell

248 Normal and idiopathic pulmonary fibrosis lung fibroblasts were trea

249 bryonic fibroblasts (MEFs) and rat and human idiopathic pulmonary fibrosis lung fibroblasts with siRN

250 Human idiopathic pulmonary fibrosis lung myofibroblasts expres

251 en shown to be highly expressed in AECs from idiopathic pulmonary fibrosis lungs although its role is

252 by both mesothelial and mesenchymal cells in idiopathic pulmonary fibrosis lungs but has limited or n

253 te that some disease progression pathways in idiopathic pulmonary fibrosis may represent partial reve

254 nnual incidence and cumulative prevalence of idiopathic pulmonary fibrosis, median survival time of p

255 ficantly higher in patients with progressive idiopathic pulmonary fibrosis (n=32) than in those with

256 fibrosis (n=71) than in patients with stable idiopathic pulmonary fibrosis (n=60) by 6 months.

257 ficantly higher in patients with progressive idiopathic pulmonary fibrosis (n=71) than in patients wi

258 In patients with idiopathic pulmonary fibrosis, nintedanib reduced the de

259 open surgery, and a provisional diagnosis of idiopathic pulmonary fibrosis or connective tissue disea

260 al cohort study (PROFILE), participants with idiopathic pulmonary fibrosis or idiopathic non-specific

261 t for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006).

262 tes of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23).

263 stingly, and of potential relevance to human idiopathic pulmonary fibrosis, PARP activity in lung fib

264 s upregulated in peripheral blood cells from idiopathic pulmonary fibrosis patients and correlated wi

265 P activity in lung fibroblasts isolated from idiopathic pulmonary fibrosis patients was significantly

266 pment and differentially expressed miRNAs in idiopathic pulmonary fibrosis patients, some of which we

267 5 and miR-186 were decreased in the lungs of idiopathic pulmonary fibrosis patients.

268 f bleomycin-treated mice and in the lungs of idiopathic pulmonary fibrosis patients.

269 valuated in an exploratory phase 2a study in idiopathic pulmonary fibrosis patients.

270 so observe a population ILC2 in the lungs of idiopathic pulmonary fibrosis patients.

271 Many patients with suspected idiopathic pulmonary fibrosis present with atypical high

272 Importantly, in a mouse model of idiopathic pulmonary fibrosis (RAGE-/-), reconstitution

273 In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortal

274 d mortality (0.0237), and treatment-emergent idiopathic-pulmonary-fibrosis-related (0.0132) mortality

275 ent-emergent all-cause mortality (p=0.0420), idiopathic-pulmonary-fibrosis-related mortality (0.0237)

276 0.35 [0.17-0.72; 0.0029]; treatment-emergent idiopathic-pulmonary-fibrosis-related mortality 0.32 [0.

277 ll-cause mortality 0.45 [0.24-0.83; 0.0094]; idiopathic-pulmonary-fibrosis-related mortality 0.35 [0.

278 is-related mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality at weeks

279 ity, treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and tre

280 -myofibroblast differentiation/activation in idiopathic pulmonary fibrosis remain poorly understood.

281 e, and was replicated in the two independent idiopathic pulmonary fibrosis replication cohorts (Chica

282 Present guidelines for the diagnosis of idiopathic pulmonary fibrosis require histological confi

283 bo-Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and

284 Susceptibility to idiopathic pulmonary fibrosis seems to involve a combina

285 kers to Estimate Time-progression (COMET) in idiopathic pulmonary fibrosis study were followed up for

286 ical Markers to Estimate Time-Progression in Idiopathic Pulmonary Fibrosis) study were used to conduc

287 TH, were higher in lungs from patients with idiopathic pulmonary fibrosis than in control individual

288 24) at baseline were higher in patients with idiopathic pulmonary fibrosis than in healthy controls.

289 Additionally, we demonstrate that in human idiopathic pulmonary fibrosis there is increased pulmona

290 tudy, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pir

291 n American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.

292 irfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis] trial), including all pat

293 radiation-induced pulmonary fibrosis and in idiopathic pulmonary fibrosis, two diseases considered t

294 Idiopathic pulmonary fibrosis was defined by Internation

295 elomere length and survival in patients with idiopathic pulmonary fibrosis was independent of age, se

296 ndpoint for clinical trials in patients with idiopathic pulmonary fibrosis who have mild-to-moderate

297 to the preservation of FVC in patients with idiopathic pulmonary fibrosis with mild-to-moderate impa

298 trial, we randomly assigned patients who had idiopathic pulmonary fibrosis with mild-to-moderate impa

299 Patients (aged 35-80 years) with idiopathic pulmonary fibrosis within 4 years of diagnosi

300 research is to develop a method to diagnose idiopathic pulmonary fibrosis without the patient having